Kinase 2014: past, present and beyond


6th RSC/SCI symposium on kinase inhibitor design
19 - 20 May 2014
The Barry Cross Conference Centre, Cambridge

Now with over twenty FDA-approved small molecules, the field of kinase inhibition has matured. The symposium on kinases encompassed case studies of ongoing programmes as well as successful past kinase programmes. Presentations included examples in the following fields:

  • CNS
  • inflammation/respiratory
  • oncology 

The question of emerging resistance to kinase inhibitors was raised along with techniques being developed to address this. 

The symposium included views, perspectives and discussions on the future of kinase inhibitor research.

Session Chairs

John Harris
CJH Consultants

Keith Jones
Institute of Cancer Research

Roger Griffin
Northern Institute for Cancer Research

Andy Thomas
AstraZeneca

Speakers

Andrew Mortlock
AstraZeneca - UK
Clinical experience with kinase inhibitors for the treatment of cancer

Sharan Bagal
Pfizer Neusentis - UK
The discovery and optimisation of a series of potent, selective and CNS restricted pan-Trk ligands for pain

Douglas Thomson
Cellzome - Germany
Chemoproteomic applications in kinase drug discovery

Chris Johnson
Astex Pharmaceuticals - UK
Fragment-based discovery of selective inhibitors of maternal embryonic leucine zipper kinase

Robert Heald
Argenta - UK
Brain penetrant PI3K inhibitors for the treatment of glioblastoma:optimisation of free brain concentrations using an MPO approach

Ian Storer
Pfizer - UK
Inhalation by design: the discovery of slow-offset Janus Kinase (JAK) inhibitors towards the treatment of respiratory diseases

Andreas Marzinzik
Novartis - Switzerland
Non-ATP site-directed kinase inhibitors

Kathleen Too
Royal Society of Chemistry
Introduction to the Royal Society of Chemistry and the Chinese Pharmaceutical Association session at Kinase 2014

Weiguo Su
Hutchinson MediPharma
Discovery and preclinical development of HMPL-504, a potent, selective and orally active c-Met inhibitor

Ke Ding
Institute of Biomedicine and Health - Guangzhou
New kinase inhibitors targeting the clinical acquired resistance related mutants

Min Huang
Shanghai Institute of Materia Medica
Luctanib: a dual kinase inhibitor targeting FGFR and VEGFR

Simon Cook
The Babraham Institute - UK
Acquired resistance to kinase inhibitors – the problem and some solutions

Russell Petter
Celgene - USA
The resurgence of covalent drugs

Ray Finlay
AstraZeneca - UK
The discovery of AZD9291: a mutant selective, third generation EGFR inhibitor

John Pollard
Vertex Pharmaceuticals - UK
Discovery and characterisation of potent and selective inhibitors of ATR kinase as anti-cancer agents

Concepcion Sanchez-Martinez
Lilly - Spain
LY2835219. A CDK4/6 dual inhibitor with unique pharmacology and physicochemical properties

Nathanael Gray
Harvard - USA
Targeting oncogenic kinases and K-RAS with covalent inhibitors


Downloadable Files

Clinical experience with kinase inhibitors for the treatment of cancer
Andrew Mortlock; AstraZeneca
PDF iconPDF (937k)  

Chemoproteomic applications in kinase drug discovery
Douglas Thomson; Cellzome
PDF iconPDF (1009k)  

New kinase inhibitors targeting the clinical acquired resistance related mutants
Ke Ding; Institute of Biomedicine and Health - Guangzhou
PDF iconPDF (1160k)  

Discovery and characterisation of potent and selective inhibitors of ATR kinase as anti-cancer agents
John Pollard; Vertex Pharmaceuticals
PDF iconPDF (2058k)  


PDF files require Link icon Adobe Acrobat Reader